Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 10/20 | 0.56 |
| ▸ | ANPEP | P15144 | 1/20 | 0.56 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.56 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13543995 | 1.00 | FOLH1 (0.56) | FOLH1ANPEPENPEPMEP1BMRGPRX4 | |
| SCHEMBL8100962 | 0.87 | SLC7A5 (0.42) | FOLH1ANPEPENPEPMEP1B | |
| SCHEMBL8095515 | 0.85 | SLC7A5 (0.41) | FOLH1ANPEPENPEPMEP1B | |
| SCHEMBL20222942 | 0.85 | FOLH1 (0.51) | FOLH1ANPEPENPEPMEP1B | |
| SCHEMBL765921 | 0.84 | FOLH1 (0.61) | FOLH1ANPEPENPEPMEP1BMRGPRX4 | |
| Isophthalic Acid SCHEMBL1790335 | 0.84 | KMT2A (0.50) | FOLH1ANPEPENPEPMEP1B | |
| SCHEMBL14478232 | 0.83 | ANPEP (0.69) | FOLH1ANPEPENPEP | |
| SCHEMBL8375490 | 0.83 | FOLH1 (0.59) | FOLH1ANPEPENPEPMEP1BMRGPRX4 | |
| SCHEMBL9622159 | 0.83 | ANPEP (0.69) | FOLH1ANPEPENPEP | |
| SCHEMBL1397444 | 0.83 | ANPEP (0.69) | FOLH1ANPEPENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120148534-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-06-14 | — | — | US | disclosed |
| US-7652023-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | FOLH1 4333/4885ANPEP 1545/4885ENPEP 1202/4885 |
| US-20120148534-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | EIF2AK2, NSUN3, NSUN2 | FOLH1 2818/4885ANPEP 1243/4885ENPEP 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.